Difference in Biomarkers Between COVID-19 Patients and Other Pulmonary Infection Patients.

Jingyi DaiYing-Rong DuJianpeng GaoJun ZhaoLin WangYing HuangJiawei XiaYu LuoShenghao LiEdward B McNeil

Published in: Infection and drug resistance (2020)

Integration of biomarkers can discriminate COVID-19 patients from other pulmonary infections on admission to hospital and thus may be a supplement to nucleic acid tests.

Keyphrases

nucleic acid
end stage renal disease
sars cov
pulmonary hypertension
ejection fraction
newly diagnosed
chronic kidney disease
emergency department
healthcare
prognostic factors
peritoneal dialysis
adverse drug